This invention relates to a method for identifying an analyte using protein nanopore.
A biological nanopore, which is the core component of a commercial sequencer[1], is capable of decoding a tremendous amount of information including length[2], sequence[3,4], base modification[5] from DNA and many other biomacromolecules including RNA[6], peptides[7] and proteins[8]. This remarkable sensing performance originates from its biological role as an ion channel[9]. Since it is the only pathway through which ions can cross the membrane, a biological nanopore could resolve chemical binding of an individual ion within the pore restriction[10], indicating a precision far greater than that of a solid state nanopore[11].
Pioneered by Bayley et al. since 1997[10], nanopore-based direct sensing of single ions such as Co2+, Ag+ or Cd2+ is performed by a designed ion-amino acid coordination[10,12,13] or an ion-chelator interaction[14] within an engineered a-hemolysin (a-HL) mutants. However, α-HL blockages by single monatomic ions of different identities show consistently shallow resistive pulses (˜2-3 pA), resulting from the cylindrical pore geometry and the small size of the analyte ions[10, 12, 13]. Alternatively, indirect sensing of metal ions can be performed with molecular adapters like DNA[15], peptides[16] or cyclodextrins[17] but with diminished signal specificity and an increased system complexity.
Chloroauric acid (HAuCl4), a well-known gold compound[18], is a precursor that is used widely for the fabrication of gold nanomaterials[18] . In an aqueous buffered solution, the dissociated tetrachloroaurate(III) ion ([AuCl4]−) is a square planar, polyatomic ion with a net charge of −1, in which the Au—Cl bond measures 2.28 Å in length[20]. Previous reports indicated that the tetrachloroaurate(III) ion is a potent aquaporin inhibitor[21] but investigations at the level of single molecules have not been reported.
One aspect of this invention provides use of a metal embedded protein nanopore in identifying an analyte in a sample.
In some embodiments, the metal embedded protein nanopore is a protein nanopore embedded one or more with metal-containing ions.
In some embodiments, the one or more metal-containing ions are selected from the group consisting of ions contain Au(III), Zn2+, Co2+, Ag2+, Cd2+, Ni2+, Au(I), Cu2+, Cr3+, Fe2+, Fe3+, Pt(II), Pd(II), Mn2+, Hg2+, Ru(II) and Pb2+.
In some embodiments, the one or more metal-containing ions are selected from the group consisting of [AuCl4]−, Zn2+, Co2+, Ag+, Cd2+, Ni2+, [AuCl2]−, Cu2+, Cr3+, Fe2+, Fe3+, Pt(II), Pd(II), Mn2+, Hg2+, Ru(II) and Pb2+ ions.
In some embodiments, the one or more metal-containing ions are bound to methionine, cysteine, histidine or any combination of them on the inner surface of the nanopore.
In some embodiments, the number of the one or more metal-containing ions which are bound to methionine, cysteine, histidine or any combination of them on the inner surface of the nanopore is 1, 2, 3, 4, 5, 6, 7, or 8.
In some embodiments, the protein nanopore is a-HL or MspA, CsgG, OmpG, Cytolysin A, ClyA, aerolysin, Frac or Phi29 connector.
In some embodiments, MspA is a mutant octameric MspA, said mutant octameric MspA comprises at least one mutant MspA monomers, said mutant octameric MspA has no spontaneous gating activities at positive voltages and has methionine, cysteine, histidine or any combination of them on the inner surface.
In some embodiments, at least one of the mutant MspA monomers comprises one or more mutations at positions 83-111 compared to the wild-type MspA monomer; preferably, the one or more mutations at positions 83-111 may be one or more mutations at position 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104 and/or 105; more preferably, at least one of the mutant MspA monomers comprises mutation at positions 88, 91 and/or 105 compared to the wild-type MspA monomer; more preferably, said mutation is a mutation to methionine, cysteine or histidine; more preferably, at least one of the mutant MspA monomers comprises the mutation of D91M, D91H or D91C compared to the wild-type MspA monomer; more preferably, at least one of the mutant MspA monomers comprises the mutations of D93N/D91M/D9ON/D118R/D134R/E139K, D93N/D91H/D9ON/D118R/D134R/E139K, or D93N/D91C/D9ON/D118R/D134R/E139K compared to the wild-type MspA monomer.
In some embodiments, the analyte is metal-containing analyte such as metal-containing ion or nucleic acid.
In some embodiments, the analyte is amino acid or peptide; preferably, the amino acid or peptide contains sulfur.In some embodiments, the amino acid contains one or more sulfur atoms on the amino acid side chain or contains thiol group; more preferable, the amino acid is L-methionine, L-cysteine or L-homocysteine. In some embodiments, the peptide contains an amino acid containing one or more sulfur atoms on the amino acid side chain or an amino acid containing thiol group; more preferable, the peptide contains L-methionine, L-cysteine or L-homocysteine.
In some embodiments, the analyte is a thiol; preferably, the analyte is a biothiol; more preferably, the biothiol is L-cysteine, L-homocysteine, and/or L-glutathione.
In some embodiments, the nucleic acid is ssDNA, dsDNA, RNA, or a combination thereof.
Another aspect of this invention provides a method of identifying an analyte in a sample is provided, the method comprising:
providing a protein nanopore positioned between a first conductive liquid medium and a second conductive liquid medium, wherein the nanopore comprises an opening that provides liquid communication between the first conductive liquid medium and the second conductive liquid medium, wherein the first conductive liquid medium or the second conductive liquid medium comprises the sample, wherein the nanopore is embedded with one or more metal-containing ions;
applying an electric field across the nanopore and translocating the analyte through the nanopore;
measuring the blockade current across the nanopore; and
identifying the analyte according to the measured blockade current.
In some embodiments, the one or more metal-containing ions are selected from the group consisting of ions contain Au(III), Zn2+, Co2+, Ag+, Cd2+, Ni2+, Au(I), Cu2+, Fe2+, Fe3+, Pt(II), Pd(II), Mn2+, Hg2+, Ru(II) and Pb2+.
In some embodiments, the one or more metal-containing ions are selected from the group consisting off ions.
In some embodiments, the one or more metal-containing ions are bound to methionine, cysteine, histidine or any combination of them on the inner surface of the nanopore.
In some embodiments, the number of the one or more metal-containing ions which are io bound to methionine, cysteine, histidine or any combination of them on the inner surface of the nanopore is 1, 2, 3, 4, 5, 6, 7, or 8.
In some embodiments, the protein nanopore is a-HL or MspA, CsgG, OmpG, Cytolysin A, ClyA, aerolysin, Frac or Phi29 connector.
In some embodiments, MspA is a mutant octameric MspA, said mutant octameric MspA comprises at least one mutant MspA monomers, said mutant octameric MspA has no spontaneous gating activities at positive voltages and has methionine, cysteine, histidine or any combination of them on the inner surface.
In some embodiments, at least one of the mutant MspA monomers comprises one or more mutations at positions 83-111 compared to the wild-type MspA monomer; preferably, the one or more mutations at positions 83-111 may be one or more mutations at position 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104 and/or 105; more preferably, at least one of the mutant MspA monomers comprises mutation at positions 88, 91 and/or 105 compared to the wild-type MspA monomer; more preferably, said mutation is a mutation to methionine, cysteine or histidine; more preferably, at least one of the mutant MspA monomers comprises the mutation of D91M, D91H or D91C compared to the wild-type MspA monomer; more preferably, at least one of the mutant MspA monomers comprises the mutations of D93N/D91M/D9ON/D118R/D134R/E139K, D93N/D91H/D9ON/D118R/D134R/E139K, or D93N/D91C/D9ON/D118R/D134R/E139K compared to the wild-type MspA monomer.
In some embodiments, the analyte is metal-containing analyte such as metal-containing ion or nucleic acid.
In some embodiments, the analyte is amino acid or peptide; preferably, the amino acid or peptide contains sulfur. In some embodiments, the amino acid contains one or more sulfur atoms on the amino acid side chain or contains thiol group; more preferable, the amino acid is L-methionine, L-cysteine or L-homocysteine. In some embodiments, the peptide contains an amino acid containing one or more sulfur atoms on the amino acid side chain or an amino acid containing thiol group; more preferable, the peptide contains L-methionine, L-cysteine or L-homocysteine.
In some embodiments, the analyte is a thiol; preferably, the analyte is a biothiol; more preferably, the biothiol is L-cysteine, L-homocysteine, and/or L-glutathione.
In some embodiments, the nucleic acid is ssDNA, dsDNA, RNA, or a combination thereof.
In some embodiments, the method comprising:
providing a protein nanopore positioned between a first conductive liquid medium and a second conductive liquid medium, wherein the nanopore comprises an opening that provides liquid communication between the first conductive liquid medium and the second conductive liquid medium, wherein the first conductive liquid medium or the second conductive liquid medium comprises the sample and metal-containing ions;
applying an electric field across the nanopore and translocating the metal-containing ions and the analyte through the nanopore;
measuring the blockade current across the nanopore; and
identifying the analyte in the sample according to the measured blockade current.
In another embodiment, the method comprising:
providing a protein nanopore positioned between a first conductive liquid medium and a second conductive liquid medium, wherein the nanopore comprises an opening that provides liquid communication between the first conductive liquid medium and the second conductive liquid medium, wherein the first conductive liquid medium or the second conductive liquid medium comprises metal-containing ions;
applying an electric field across the nanopore and translocating the metal-containing ions through the nanopore;
adding the sample into the conductive liquid medium which comprises the metal-containing contianing ion initially and translocating the analyte through the nanopore;
measuring the blockade current across the nanopore; and
identifying the analyte in the sample according to the measured blockade current.
In some embodiments, the metal-containing ions are one or more selected from the group consisting of ions contain Au(III), Zn2+, Co2+, Ag+, Cd2+, Ni2+, Au(I), Cu2+, Fe2+, Fe3+, Pt(II), Pd(II), Mn2+, Hg2+, Ru(II) and Pb2+.
In some embodiments, the metal-containing ions are one or more selected from the group consisting of [AuCl4]−, Zn2+, Co2+, Ag+, Cd2+, Ni2+, [AuCl2]−, Cu2+, Cr3+, Fe2+, Fe3+, Pt(II), Pd(II), Mn2+, Hg2+, Ru(II) and Pb2+ ions.
In some embodiments, the protein nanopore is α-HL or MspA, CsgG, OmpG, Cytolysin A, ClyA, aerolysin, Frac or Phi29 connector.
In some embodiments, MspA is a mutant octameric MspA, said mutant octameric MspA comprises at least one mutant MspA monomers, said mutant octameric MspA has no spontaneous gating activities at positive voltages and has methionine, cysteine, histidine or any combination of them on the inner surface.
In some embodiments, at least one of the mutant MspA monomers comprises one or more mutations at positions 83-111 compared to the wild-type MspA monomer; preferably, the one or more mutations at positions 83-111 may be one or more mutations at position 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104 and/or 105; more preferably, at least one of the mutant MspA monomers comprises mutation at positions 88, 91 and/or 105 compared to the wild-type MspA monomer; more preferably, said mutation is a mutation to methionine, cysteine or histidine; more preferably, at least one of the mutant MspA monomers comprises the mutation of D91M, D91H or D91C compared to the wild-type MspA monomer; more preferably, at least one of the mutant MspA monomers comprises the mutations of
D93N/D91M/D9ON/D118R/D134R/E139K, D93N/D91H/D9ON/D118R/D134R/E139K, or D93N/D91C/D9ON/D118R/D134R/E139K compared to the wild-type MspA monomer.
In some embodiments, the analyte is metal-containing analyte such as metal-containing ion or nucleic acid.
In some embodiments, the analyte is amino acid or peptide; preferably, the amino acid or peptide contains sulfur. In some embodiments, the amino acid contains one or more sulfur atoms on the amino acid side chain or contains thiol group; more preferable, the amino acid is L-methionine, L-cysteine or L-homocysteine. In some embodiments, the peptide contains an amino acid containing one or more sulfur atoms on the amino acid side chain or an amino acid containing thiol group; more preferable, the peptide contains L-methionine, L-cysteine or L-homocysteine.
In some embodiments, the analyte is a thiol; preferably, the analyte is a biothiol; more preferably, the biothiol is L-cysteine, L-homocysteine, and/or L-glutathione.
In some embodiments, the nucleic acid is ssDNA, dsDNA, RNA, or a combination thereof.
Another aspect of this invention provides a system of identifying an analyte in a sample, the system contains a protein nanopore positioned between a first conductive liquid medium and a second conductive liquid medium, wherein the nanopore comprises an opening that is provides liquid communication between the first conductive liquid medium and the second conductive liquid medium, wherein the first conductive liquid medium or the second conductive liquid medium comprises the sample, wherein the nanopore is embedded with one or more metal-containing ion.
In some embodiments, the one or more metal-containing ions are selected from the group consisting of ions contain Au(III), Zn2+, Co2+, Ag+, Cd2+, Ni2+, Au(I), Cu2+, Fe2+, Fe3+, Pt(II), Pd(II), Mn2+, Hg2+, Ru(II) and Pb2+.
In some embodiments, the one or more metal-containing ions are selected from the group consisting of [AuCl4]−, Zn2+, Co2+, Ag+, Cd2+, Ni2+, [AuCl2]−, Cu2+, Cr3+, Fe2+, Fe3+, Pt(II), Pd(II), Mn2+, Hg2+, Ru(II) and Pb2+ ions.
In some embodiments, the one or more metal-containing ions are bound to methionine, cysteine, histidine or any combination of them on the inner surface of the nanopore.
In some embodiments, the number of the one or more metal-containing ions which are bound to methionine, cysteine, histidine or any combination of them on the inner surface of the nanopore is 1, 2, 3, 4, 5, 6, 7, or 8.
In some embodiments, the protein nanopore is a-HL or MspA, CsgG, OmpG, Cytolysin A, ClyA, aerolysin, Frac or Phi29 connector.
In some embodiments, MspA is a mutant octameric MspA, said mutant octameric MspA comprises at least one mutant MspA monomers, said mutant octameric MspA has no spontaneous gating activities at positive voltages and has methionine, cysteine, histidine or any combination of them on the inner surface.
In some embodiments, at least one of the mutant MspA monomers comprises one or more mutations at positions 83-111 compared to the wild-type MspA monomer; preferably, the one or more mutations at positions 83-111 may be one or more mutations at position 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104 and/or 105; more preferably, at least one of the mutant MspA monomers comprises mutation at positions 88, 91 and/or 105 compared to the wild-type MspA monomer; more preferably, said mutation is a mutation to methionine, cysteine or histidine; more preferably, at least one of the mutant MspA monomers comprises the mutation of D91M, D91H or D91C compared to the wild-type MspA monomer; more preferably, at least one of the mutant MspA monomers comprises the mutations of D93N/D91M/D9ON/D118R/D134R/E139K, D93N/D91H/D9ON/D118R/D134R/E139K, or D93N/D91C/D9ON/D118R/D134R/E139K compared to the wild-type MspA monomer.
In some embodiments, the analyte is metal-containing analyte such as metal-containing ion or nucleic acid.
In some embodiments, the analyte is amino acid or peptide; preferably, the amino acid or peptide contains sulfur. In some embodiments, the amino acid contains one or more sulfur atoms on the amino acid side chain or contains thiol group; more preferable, the amino acid is L-methionine, L-cysteine or L-homocysteine. In some embodiments, the peptide contains an amino acid containing one or more sulfur atoms on the amino acid side chain or an amino acid io containing thiol group; more preferable, the peptide contains L-methionine, L-cysteine or L-homocysteine.
In some embodiments, the analyte is a thiol; preferably, the analyte is a biothiol; more preferably, the biothiol is L-cysteine, L-homocysteine, and/or L-glutathione.
In some embodiments, the nucleic acid is ssDNA, dsDNA, RNA, or a combination thereof.
In some embodiments, the system contains a protein nanopore positioned between a first conductive liquid medium and a second conductive liquid medium, wherein the nanopore comprises an opening that provides liquid communication between the first conductive liquid medium and the second conductive liquid medium, wherein the first conductive liquid medium or the second conductive liquid medium comprises the sample and metal-containing ions.
In another embodiment, the system contains a protein nanopore positioned between a first conductive liquid medium and a second conductive liquid medium, wherein the nanopore comprises an opening that provides liquid communication between the first conductive liquid medium and the second conductive liquid medium, wherein the first conductive liquid medium or the second conductive liquid medium comprises metal-containing ions.
In some embodiments, the metal-containing ions are one or more selected from the group consisting of ions contain Au(III), Zn2+, Co2+, Ag+, Cd2+, Ni2+, Au(I), Cu2+, Fe2+, Fe3+, Pt(II), Pd(II), Mn2+, Hg2+, Ru(II) and Pb2+.
In some embodiments, the metal-containing ions are one or more selected from the group consisting of [AuCl4]−, Zn2+, Co2+, Ag+, Cd2+, Ni2+, [AuCl2]−, Cu2+, Cr3+, Fe2+, Fe3+, Pt(II), Pd(II), Mn2+, Hg2+, Ru(II) and Pb2+ ions.
In some embodiments, the protein nanopore is α-HL or MspA, CsgG, OmpG, Cytolysin A, ClyA, aerolysin, Frac or Phi29 connector.
In some embodiments, MspA is a mutant octameric MspA, said mutant octameric MspA comprises at least one mutant MspA monomers, said mutant octameric MspA has no spontaneous gating activities at positive voltages and has methionine, cysteine, histidine or any combination of them on the inner surface.
In some embodiments, at least one of the mutant MspA monomers comprises one or more mutations at positions 83-111 compared to the wild-type MspA monomer; preferably, the one or more mutations at positions 83-111 may be one or more mutations at position 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104 and/or 105; more preferably, at least one of the mutant MspA monomers comprises mutation at positions 88, 91 and/or 105 compared to the wild-type MspA monomer; more preferably, said mutation is a mutation to methionine, cysteine or histidine; more preferably, at least one of the mutant MspA monomers comprises the mutation of D91M, D91H or D91C compared to the wild-type MspA monomer; more preferably, at least one of the mutant MspA monomers comprises the mutations of D93N/D91M/D9ON/D118R/D134R/E139K, D93N/D91H/D9ON/D118R/D134R/E139K, or D93N/D91C/D9ON/D118R/D134R/E139K compared to the wild-type MspA monomer.
In some embodiments, the analyte is metal-containing ion analyte such as metal-containing or nucleic acid.
In some embodiments, the analyte is amino acid or peptide; preferably, the amino acid or peptide contains sulfur. In some embodiments, the amino acid contains one or more sulfur atoms on the amino acid side chain or contains thiol group; more preferable, the amino acid is L-methionine, L-cysteine or L-homocysteine. In some embodiments, the peptide contains an amino acid containing one or more sulfur atoms on the amino acid side chain or an amino acid containing thiol group; more preferable, the peptide contains L-methionine, L-cysteine or L-homocysteine.
In some embodiments, the analyte is a thiol; preferably, the analyte is a biothiol; more is preferably, the biothiol is L-cysteine, L-homocysteine, and/or L-glutathione.
In some embodiments, the nucleic acid is ssDNA, dsDNA, RNA, or a combination thereof.
Another aspect of this invention provides a kit for identifying an analyte, the kit containing: (1) metal-containing compound; and (2) a protein that can form a nanopore or a nucleic acid, expression vector or recombinant host cell that can express a protein that can form a nanopore; said metal-containing compound is capable of forming metal-containing ions in a solution.
In some embodiments, the metal-containing compound contains Au(III), Zn2+, Co2+, Ag+, Cd2+, Ni2+, Au(I), Cu2+, Cr3+, Fe2+, Fe3+, Pt(II), Pd(II), Mn2+, Hg2+, Ru(II) or Pb2+.
In some embodiments, the metal-containing compound is capable of forming [AuCl4]−, Zn2+, Co2+, Ag+, Cd2+, Ni2+, [AuCl2]−, Cu2+, Cr3+, Fe2+, Fe3+, Pt(II), Pd(II), Mn2+, Hg2+, Ru(II) or Pb2+ ions in a solution.
In some embodiments, the metal-containing compound may be chloroauric acid or tetrachloroaurate(III).
In some embodiments, the protein is a-HL or MspA, CsgG, OmpG, Cytolysin A, ClyA, aerolysin, Frac or Phi29 connector.
In some embodiments, MspA is a mutant octameric MspA, said mutant octameric MspA comprises at least one mutant MspA monomers, said mutant octameric MspA has no spontaneous gating activities at positive voltages and has methionine, cysteine, histidine or any combination of them on the inner surface.
In some embodiments, at least one of the mutant MspA monomers comprises one or more mutations at positions 83-111 compared to the wild-type MspA monomer; preferably, the one or more mutations at positions 83-111 may be one or more mutations at position 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104 and/or 105; more preferably, at least one of the mutant MspA monomers comprises mutation at positions 88, 91 and/or 105 compared to the wild-type MspA monomer; more preferably, said mutation is a mutation to methionine, cysteine or histidine; more preferably, at least one of the mutant MspA monomers comprises the mutation of D91M, D91H or D91C compared to the wild-type MspA monomer; more preferably, at least one of the mutant MspA monomers comprises the mutations of D93N/D91M/D9ON/D118R/D134R/E139K, D93N/D91H/D9ON/D118R/D134R/E139K, or D93N/D91C/D9ON/D118R/D134R/E139K compared to the wild-type MspA monomer.
In some embodiments, the analyte is metal-containing analyte such as metal-containing ion or nucleic acid. In some embodiments, the analyte is amino acid or peptide; preferably, the amino acid or peptide contains sulfur. In some embodiments, the amino acid contains one or more sulfur atoms on the amino acid side chain or contains thiol group; more preferable, the amino acid is L-methionine, L-cysteine or L-homocysteine. In some embodiments, the peptide contains an amino acid containing one or more sulfur atoms on the amino acid side chain or an amino acid containing thiol group; more preferable, the peptide contains L-methionine, L-cysteine or L-homocysteine.
In some embodiments, the analyte is a thiol; preferably, the analyte is a biothiol; more preferably, the biothiol is L-cysteine, L-homocysteine, and/or L-glutathione.
In some embodiments, the nucleic acid is ssDNA, dsDNA, RNA, or a combination thereof.
Another aspect of this invention provides use of MspA in identifying a metal-containing ion in a sample.
In some embodiments, the metal-containing ion are selected from the group consisting of ions contain Au(III), Zn2+, Co2+, Ag+, Cd2+, Ni2+, Au(I), Cu2+, Cr3+, Fe2+, Fe3+, Pt(II), Pd(II), Mn2+, Hg2+, Ru(II) and Pb2+.
In some embodiments, MspA is a mutant octameric MspA, said mutant octameric MspA comprises at least one mutant MspA monomers, said mutant octameric MspA has no spontaneous gating activities at positive voltages and has methionine, cysteine, histidine or any combination of them on the inner surface.
In some embodiments, at least one of the mutant MspA monomers comprises one or more mutations at positions 83-111 compared to the wild-type MspA monomer; preferably, the one or more mutations at positions 83-111 may be one or more mutations at position 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104 and/or 105; more preferably, at least one of the mutant MspA monomers comprises mutation at positions 88, 91 and/or 105 compared to the wild-type MspA monomer; more preferably, said mutation is a mutation to methionine, cysteine or histidine; more preferably, at least one of the mutant MspA monomers comprises the mutation of D91M, D91H or D91C compared to the wild-type MspA monomer; more preferably, at least one of the mutant MspA monomers comprises the mutations of D93N/D91M/D9ON/D118R/D134R/E139K, D93N/D91H/D9ON/D118R/D134R/E139K, or D93N/D91C/D9ON/D118R/D134R/E139K compared to the wild-type MspA monomer.
Another aspect of this invention provides method of identifying a metal-containing ion in a sample, the method comprising:
providing a MspA positioned between a first conductive liquid medium and a second conductive liquid medium, wherein the MspA comprises an opening that provides liquid communication between the first conductive liquid medium and the second conductive liquid medium, wherein the first conductive liquid medium or the second conductive liquid medium comprises the sample;
applying an electric field across the MspA and translocating the metal-containing ion through the nanopore;
measuring the blockade current across the nanopore; and
identifying the metal-containing ion in the sample according to the measured blockade current.
In some embodiments, the metal-containing ion are selected from the group consisting of ions contain Au(III), Zn2+, Co2+, Ag+, Cd2+, Ni2+, Au(I), Cu2+, Cr3+, Fe2+, Fe3+, Pt(II), Pd(II), Mn2+, Hg2+, Ru(II) and Pb2+.
In some embodiments, MspA is a mutant octameric MspA, said mutant octameric MspA comprises at least one mutant MspA monomers, said mutant octameric MspA has no spontaneous gating activities at positive voltages and has methionine, cysteine, histidine or any combination of them on the inner surface.
In some embodiments, at least one of the mutant MspA monomers comprises one or more mutations at positions 83-111 compared to the wild-type MspA monomer; preferably, the one or more mutations at positions 83-111 may be one or more mutations at position 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104 and/or 105; more preferably, at least one of the mutant MspA monomers comprises mutation at positions 88, 91 and/or 105 compared to the wild-type MspA monomer; more preferably, said mutation is a mutation to methionine, cysteine or histidine; more preferably, at least one of the mutant MspA monomers comprises the mutation of D91M, D91H or D91C compared to the wild-type MspA monomer; more preferably, at least one of the mutant MspA monomers comprises the mutations of D93N/D91M/D9ON/D118R/D134R/E139K, D93N/D91H/D9ON/D118R/D134R/E139K, or D93N/D91C/D9ON/D118R/D134R/E139K compared to the wild-type MspA monomer.
Another aspect of this invention provides system of identifying a metal-containing ion in a sample, the system contains a MspA positioned between a first conductive liquid medium and a second conductive liquid medium, wherein the MspA comprises an opening that provides liquid communication between the first conductive liquid medium and the second conductive liquid medium, wherein the first conductive liquid medium or the second conductive liquid medium comprises the sample.
In some embodiments, the metal-containing ion are selected from the group consisting of ions contain Au(III), Zn2+, Co2+, Ag+, Ni2+, Au(I), Cu2+, Cr3+, Fe2+, Fe3+, Pt(II), Pd(II), Mn2+, Hg2+, Ru(II) and Pb2+.
In some embodiments, MspA is a mutant octameric MspA, said mutant octameric MspA comprises at least one mutant MspA monomers, said mutant octameric MspA has no spontaneous gating activities at positive voltages and has methionine, cysteine, histidine or any combination of them on the inner surface. In some embodiments, at least one of the mutant MspA monomers comprises one or more mutations at positions 83-111 compared to the wild-type MspA monomer; preferably, the one or more mutations at positions 83-111 may be one or more mutations at position 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104 and/or 105; more preferably, at least one of the mutant MspA monomers comprises mutation at positions 88, 91 and/or 105 compared to the wild-type MspA monomer; more preferably, said mutation is a mutation to methionine, cysteine or histidine; more preferably, at least one of the mutant MspA monomers comprises the mutation of D91M, D91H or D91C compared to the wild-type MspA monomer; more preferably, at least one of the mutant MspA monomers comprises the mutations of D93N/D91M/D9ON/D118R/D134R/E139K, D93N/D91H/D9ON/D118R/D134R/E139K, or D93N/D91C/D9ON/D118R/D134R/E139K compared to the wild-type MspA monomer.
Scatter plot of absolute blocked depth vs dwell time and the corresponding current drop amplitude histograms for different numbered levels. (c, d) Mean 66 I/I0 and dwell time for ssDNA translocation events from different level n. All means and standard deviations are from three independent experiments (10 minutes recording, N=3, Table 8). The image inset in d shows an expanded view for level 0-2.
Hcy binding. The definition of ΔI and I0 is the same as that described in
Resistive pulse signals in the trace represent GSH binding with the pore. Blue dots mark the events concerning GSH. Other unlabeled events are background signals as described in
Cys and blue dots mark those of GSH. The grey star marks binding events from one or two [AuCl4]−. (f) The scatter plot of the dwell time vs the ΔI/I0 with the corresponding amplitude histogram from the simultaneous recording of Cys and GSH as a mixture with 10 μM and 30 μM in trans respectively. The statistical data were derived from a continuous 10 min recording.
This invention demonstrates that wild-type (WT) α-HL is a natural [AuCl4]−1 sensor as a result of the coordination of Au[III] with methionine(113). This sensing mechanism can be transplanted to the MspA nanopore[22, 23] with a significantly amplified event amplitude, up to ˜54.88 pA. MspA with Au(III) embedment continues to permit ssDNA (e.g. Table 6) translocation by geometric modulation of the pore restriction with atomic accuracy. Highly specific recognition of L-methionine by MspA is also demonstrated in assistance of Au(III) embedment, which may inspire a new approach for nanopore based protein sequencing. To the best of our knowledge, single ion interactions of Au(III) with a biological nanopore have never been investigated. Binding of tetrachloroaurate(III) within an engineered MspA nanopore is also the largest event amplitude reported from a single ion. Studies of this first hybrid biological pore embedded with Au(III) species may further inspire novel applications by merging the sensing features of biological nanopores and gold to produce a “gold biological nanopore”.
A protein nanopore can be used to detect single molecule. Some proteins can self-assemble in a lipid bilayer membrane to form a nanopore with a vestibule and a limiting aperture. The limiting aperture of the nanopore allows single molecules such as single ion or single-stranded nucleic acid molecule to pass through. In an aqueous ionic salt solution such as KCl, when an appropriate voltage is applied across the membrane, the pore formed by the nanopore channel conducts a sufficiently strong and steady ionic current. The single molecule is driven through the pore by the applied electric field, thus blocking or reducing the ionic current which can be detected. The duration of the blockade and the signal strength is related to the identity of the single molecule, such as the identity of metal-containing ion or the four bases (A, C, G and T) composition of a nucleic acid. The duration of the blockade and the signal strength also can be related to the identity of the single molecule, such as the identity of any amino acid such as L-methionine.
In the invention, the term “nanopore” refers to a pore having an opening at its narrowest point having a diameter when molecule of interest pass through the opening, the passage of the molecule can be detected by a change in signal, for example, electrical signal, e.g. current. In some cases, the nanopore is formed by protein within a membrane which may be referred to protein nanopore. Examples of protein nanopore or protein which can form a nanopore include io alpha-hemolysin, MspA, CsgG, OmpG, Cytolysin A, ClyA, aerolysin, Frac or Phi29 connector. The protein nanopore can be modified or unmodified. The protein nanopore can be modified by mutation in one or more amino acids. In some embodiments, the protein nanopore may be mutated in one or more amino acids on the inner surface. Generally, protein nanopore has vestibule and constriction zone. In some cases, the nanopore is disposed within a membrane, or is lipid bilayer. In some embodiments, the protein has a conically shaped passage which acts as a conically shaped biological nanopore.
In the invention, the protein used preferably can insert spontaneously into the membrane to form a nanopore. The protein nanopore used in this invention preferably has no spontaneous gating activities at positive voltages (up to +200 mV) and/or preferably keeps open at positive applied voltages with open pore conductance. The protein nanopore used in this invention preferably may have one or more amino acid residues which can interact with the metal ion on the inner surface of the nanopore channel. The protein nanopore may be modified to have one or more amino acid residues which can interact with the metal ion on the inner surface. One or more amino acid residues on the inner surface of the protein nanopore may be mutated to amino acid residues which can interact with the metal ion, such as methionine, cysteine or histidine. In some embodiments, the protein nanopore may have methionine, cysteine or histidine on the inner surface.
In the invention, the term “α-hemolysin”, is also referred to as a-HL, may be selected from the group consisting of a wild-type α-hemolysin, a mutant a-hemolysin, a wild-type α-hemolysin paralog or homolog hemolysin, and a mutant a-hemolysin paralog or homolog hemolysin. In some embodiments, a-hemolysin may be the wild-type a-hemolysin. The α-hemolysin that may be used in the invention should be capable of forming nanopore.
In the invention, the term “MspA”, “MspA porin” and “MspA nanopore”can be used interchangebly and refers to Mycobacterium smegmatis porin A (MspA). As known by the person skilled in the art, a MspA porin can comprise two or more MspA monomers (e.g., eight monomers), which associate with each other and form a tunnel, wherein each monomer may be the same of different. MspA may be an octameric MspA. The MspA porin that may be used in the invention should be capable of forming nanopore. Any one MspA monomer that formed the MspA porin may be selected from the group consisting of a wild-type MspA monomer, a mutant MspA monomer, a wild-type MspA paralog or homolog monomer, or a mutant MspA paralog or homolog monomer. In some embodiments, all monomers in a MspA porin are the same, such as the same mutant MspA monomers.
In this invention, the term “mutant MspA” refers to a mutant of wild type MspA. Wild type MspA is comprised of wild type MspA monomers. Mutant MspA may comprises at least one mutant MspA monomers, and the remaining monomers in the mutant MspA may be selected from the group consisting of a wild-type MspA monomer, a mutant MspA monomer, a wild-type MspA paralog or homolog monomer, or a mutant MspA paralog or homolog monomer. Mutant MspA may comprise two or more MspA monomers (e.g., eight monomers) and mutant MspA may be an octameric MspA.
In some embodiments, in a mutant MspA porin, one or more monomers are mutant MspA monomers and the other monomers are wild-type MspA monomers. In some embodiments, the MspA porin is comprised of eight mutant MspA-M monomer. When a MspA comprises more than one mutant MspA monomers, said more than on mutant MspA monomers may be the io same or different.
MspA porin may be mutated for metal embedment. In principle, every amino acids within an MspA nanopore could be engineered for metal embedment. Due to the conical geometry of the MspA nanopore, site 83 to site 111, which forms the pore constriction are preferred engineering sites. Therefore, introduction of amino acid(s) suitable for metal embedment, such as methionine, cysteine or histidine, at any one or more residue of site 83 to site 111 would significantly amplify binding signals around the pore restriction at these residues. Residue 91 is the narrowest spot of MspA, introduction of amino acid(s) suitable for metal embedment at residue 91 would result in an excellent signal amplification. Mutation at residue 88 to 105 would render similar effect with residue 91. In some embodiments, the mutant MspA monomer may comprise one or more mutations at positions 83-111 of MspA. In some embodiments, at least one of the mutant MspA monomers (e.g., all of eight mutant MspA monomers) in a mutant MspA may comprise one or more mutations at position 83-111. In some embodiments, the one or more mutations at positions 83-111 may be one or more mutations at position 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110 and/or 111. In some embodiments, the one or more mutations at positions 83-111 may be one or more mutations at position 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104 and/or 105. In some embodiments, the one or more mutations at positions 83-111 may be one or more mutations at position 88, 91 and/or 105. In some embodiments, the mutation at any position of site 83-111 may be independently the mutation from the natural residue to the amino acid suitable for metal embedment, such as methionine, cysteine or histidine. In addition to the mutation(s) at position 83-111, the mutant MspA monomer can also comprise mutation(s) at any other positions. The mutant MspA monomer may only has the mutation(s) at position 83-111 compared to the wild-type MspA monomer. The one or more mutations at position 83-111 may be mutation to methionine, cysteine, histidine or any combination of them.
In some embodiments, the mutant MspA monomer may be a mutant MspA monomer which comprises a mutation of D91M, D91H or D91C. In some embodiments, at least one of the mutant MspA monomers (e.g., all of eight mutant MspA monomers) in a mutant MspA may comprise a mutation of D91M, D91H or D91C. In some embodiments, the mutant MspA monomer may be the mutant MspA-M monomer which comprises the mutations of D93N/D91M/D9ON/D118R/D134R/E139K, D93N/D91H/D9ON/D118R/D134R/E139K, or D93N/D91C/D9ON/D118R/D134R/E139K compared to the wild-type MspA monomer. In some embodiments, at least one of the mutant MspA monomers (e.g., all of eight mutant MspA monomers) in a mutant MspA may comprise the mutations of D93N/D91M/D9ON/D118R/D134R/E139K, D93N/D91H/D9ON/D118R/D134R/E139K, or D93N/D91C/D9ON/D118R/D134R/E139K compared to the wild-type MspA monomer. In some embodiments, the mutant MspA monomer may be the mutant MspA-M monomer which only has the mutations of D93N/D91M/D9ON/D118R/D134R/E139K, D93N/D91H/D9ON/D118R/D134R/E139K, or D93N/D91C/D9ON/D118R/D134R/E139K compared to the wild-type MspA monomer. In some embodiments, at least one of the mutant MspA monomers (e.g., all of eight mutant MspA monomers) in a mutant MspA may only has the mutations of D93N/D91M/D9ON/D118R/D134R/E139K, D93N/D91H/D9ON/D118R/D134R/E139K, or D93N/D91C/D9ON/D118R/D134R/E139K compared to the wild-type MspA monomer. D93N/D91M/D9ON/D118R/D134R/E139K, D93N/D91H/D9ON/D118R/D134R/E139K, or D93N/D91C/D9ON/D118R/D134R/E139K means that the mutant comprises simultaneously all of these six mutations. The number used here identifies the location of site directed mutagenesis, where the first amino acid immediately after the start codon is defined as 1.
Sequences of wild type MspA monomers are known by the person skilled in the art. For example, Sequences of wild type MspA monomers can be found in GenBank on https://www.ncbi.nlm.nih.gov/. In some embodiments, the wild-type MspA porin monomer may have the following amino acid sequence:
In some embodiments, the wild-type MspA porin monomer may be consisted of SEQ ID NO: 1.
The preparation method of a-hemolysin or MspA is known by the person skilled in the art, for example, it could be prepared by prokaryote expression and easily purified by chromatography.
In one aspect of this invention, the inventors have found that MspA can sense tetrachloroaurate(III) ions with more amplified resistive pulses (up to 54.88 pA) due to the focusing geometry of MspA. Therefore, it is believed that MspA nanopore can be used as a good metal-containing ion sensor.
Ion that can be identified by MspA nanopore may be any metal-containing ion. Said metal-containing ion may include metal ion and complex ion formed by metal and other ion. In some embodiments, the metal-containing ion that can be identified by MspA nanopore may contains Au(III), i.e. trivalent gold ion, such as Au'. In some embodiments, the metal-containing ion that can be identified by MspA nanopore may be tetrachloroaurate(III) ion. In some embodiments, the metal-containing ion that can be identified by MspA nanopore may include Zn2+, Co2+, Ag+, Cd2+, Ni2+, Au(I) such as [AuCl2]−, Cu2+, Fe2+, Pt(II), Pd(II), Mn2+, Hg2+, R(II) or Pb2+.
In another aspect of this invention, the inventors have found that tetrachloroaurate(III) embedded MspA nanopores are capable of translocating [AuCl4]−1 or ssDNA with enlarged blockage amplitude and enhanced capture rate due to a channel cavity which has been finely tuned by metal-containing ion embedding. Therefore, it is believed that protein nanopore embedded with metal can be used to identify an analyte with better sensitivity.
In this invention, the protein nanopore may be a protein nanopore embedded with metal. Metal adhesion on the inner surface of the protein nanopore narrows the channel of the nanopore and amplifies the signal change when the analyte translocates through the nanopore. Said metal can interact with one or more amino acid residues (such as methionine, cysteine and/or histidine) on the inner surface of the nanopore channel. The metal used in this invention may be the metal that can interact with any one of the amino acid residues (such as methionine, cysteine and/or histidine) on the inner surface of the nanopore channel.
In principle, any metal-amino acid interaction may be used for the method of the present invention. If a metal is capable of interacting with an amino acid, the ion containing said metal can be used to modify the nanopore that contain said amino acid on the inner surface to form the metal embedded protein nanopore of the present invention. It should be understood that many metal-containing ions and many protein nanopores can be used and are not limited to the examples illustrated in the present invention, providing that the metal-containing ions are capable of interacting with the amino acid on the inner surface of the nanopore. It has been known that many metal ions are capable of interacting with the group of the amino acid or with the structure formed by several amino acids, such as transition metal ions are easy to coordinates with the amino acids. The metal-containing ions used in the present invention include, but is not limited to ions containing transition metal, such as transition metal ions. Metal ions' coordination to specific groups may be predicted, for example by the theory of HSAB which was first proposed by Pearson in 1963[64] and its principle is that “hard acids prefer to coordinate to hard bases, and soft acids to soft bases”. HSAB theory is mainly applied to give a qualitative prediction or interpretation for the coordination results. Metal ions' coordination to specific groups may also be proved by an experiment of interaction.
In the invention, the term “interact with” refers to that the metal may bind to any amino acid residue or any structure formed by the amino acids on the inner surface of the protein nanopore in any way, for example, in a reversible way or in an irreversible way.
The metal that is embedded on the inner surface of the nanopore may be in the form of metal-containing ion and may be any suitable metal-containing ion. Said metal-containing ion include metal ion and complex ion formed by metal and other ions. The type of metal-contain ions which are bound to the amino acid residue on the inner surface of the protein nanopore may be one or more. The number of metal-contain ions which are bound to the amino acid residue on the inner surface of the protein nanopore may be one or more, e.g. 1, 2, 3, 4, 5, 6, 7, or 8. The inventor has found that a great number of metal-containing ions bound to the inner surface of the nanopore will result in larger pore blockage amplitudes and more significant amplification of the signal change when the analyte translocates through the nanopore.
Many metal-containing ions can be bound to the amino acid of the inner surface of the nanopore and narrow the pore restriction, thereby amplify the pore blockage amplitude due to an increased electric field around the sensing spot where the analyte binds. In some embodiments, the metal-containing ions that are bound to the inner surface of the nanopore may contain Au(III), such as Au'. In some embodiments, the metal-containing ions that are bound to the inner surface of the nanopore may be tetrachloroaurate(III) ion (that is [AuCl4]−). [AuCl4]−1 ion may be bound to methionine and /or cysteine on the inner surface of the nanopore. In some embodiments, the number of [AuCl4]−1 ion molecules which are bound to methionine and/or cysteine on the inner surface of the nanopore is 1, 2, 3, 4, 5, 6, 7, or 8. Based on similar principle, in some embodiments, the metal-containing ions that are bound to the inner surface of the nanopore may contain or be Zn2+, Co2+, Ag+, Cd2+, Ni2+, Au(I) such as [AuCl2]−, Cu2+, Cr3+, Fe2+, Fe3+, Pt(II), Pd(II), Mn2+, Hg2+, Ru(II) or Pb2+. Zn2+, Cd2+, Co2+, Ni2+, or Pb2+ ion may be bound to histidine on the inner surface of the nanopore. Zn2+, Cd2+, or Pb2+ ion may be bound to cysteine on the inner surface of the nanopore. In some embodiments, one or more metal-containing ions may be bound to more than one amino acid residue on the inner surface of the protein nanopore to enhance the amplification effect. Therefore, the protein nanopore may have more than one amino acid residue on the inner surface that can interact with the metal-containing ions. The metal-containing ions bound to the same site may be the same or different. The metal-containing ions bound to different site may be the same or different.
The protein nanopore embedded with metal and the method of this invention can be used to detect analyte in a single molecule. In this invention, said analyte may be capable of passing through a nanopore channel in a single molecule under an electric field and causing a change in current through the nanopore.
In any embodiment herein, the analyte may be a nucleotide, a nucleic acid, an amino acid, a peptide, a protein, a polymer, a drug, an ion, a pollutant, a nanoscopic object, or a biological warfare agent. In some embodiments, the analyte may be metal-containing analyte, such as metal-containing ion. Said metal-containing ion may include metal ion and complex ion formed by metal and other ions. In some embodiments, the metal-containing ion that can be identified by the protein nanopore embedded with metal may contains Au(III) such as Au3+. In some embodiments, the metal-containing ion that can be identified by the protein nanopore embedded with metal may be tetrachloroaurate(III) ion. In some embodiments, the metal-containing ion that can be identified by the protein nanopore embedded with metal may contains Zn2+, Co2+, Ag+, Cd2+, Ni2+, Au(I) such as [AuCl2]−, Cu2+, Cr3+, Fe2+, Fe3+, Pt(II), Pd(II), Mn2+, Hg2+, Ru(II) or Pb2+. In some embodiments, the analyte is a polymer, such as a protein, a peptide, or a nucleic acid. Optionally, the polymer is a nucleic acid. The nucleic acid may be ssDNA, dsDNA, RNA, or a combination thereof. Optionally, the polymer is a peptide or a protein.
According to the invention, the metal embedded in the nanopore may be a metal-containing ion. The analyte to be detected may be a metal-containing analyte, such as a metal-containing ion. The metal embedded in the nanopore may be the same with or be different from the metal to be detected. For example, the metal embedded in the nanopore and the metal to be detected may be independently selected from the group consisting of Au(III), Zn2+, Co2+, Ag+, Cd2+, Ni2+, Au(I), Cu2+, Cr3+, Fe3+, Fe3+, Pt(II), Pd(II), Mn2+, Hg2+, Ru(II) and Pb2+, e.g. [AuCl4]−1 or [AuCl2]− ion.
When the analyte is nucleic acid such as ssDNA, different nucleotides may cause different current changes when passing through the nanopore, which enables sequencing of the nucleic acid. Thus, the protein nanopore embedded with metal and the method of this invention can be used to sequence a nucleic acid such as ssDNA. In some embodiments, the ssDNA can be in any length, for example, 1 nucleotide or more in length, 2 nucleotides or more in length, 3 nucleotides or more in length, 4 nucleotides or more in length, 5 nucleotides or more in length, 10 nucleotides or more in length, 20 nucleotides or more in length, 30 nucleotides or more in length, 40 nucleotides or more in length, 50 nucleotides or more in length, 70 nucleotides or more in length, 100 nucleotides or more in length. In some embodiments, the ssDNA is short oligomeric nucleic acid, such as miRNA, siRNA or short DNA probe.
The analyte to be detected may be an amino acid, such as an amino acid containing sulfur. The amino acid may be natural or non-natural. The amino acid may contain natural basic group or non-natural basic group. The amino acid may be selected from 20 kinds of amino acids that make up proteins or from other kinds of amino acids. In some embodiments, the analyte to be detected may be an amino acid having one or more sulfur atoms on the side chain. In some embodiments, the analyte to be detected may be an amino acid having —SH group. In some embodiment, the analyte to be detected may be L-methionine, L-cysteine, L-homocysteine or any other amino acids.
The analyte to be detected may be a peptide or a protein. When the analyte is a peptide or a protein, different amino acids may cause different current changes when passing through the nanopore, which enables sequencing of the peptide or protein. Thus, the protein nanopore embedded with metal and the method of this invention can be used to sequence a peptide or a protein. In some embodiments, the analyte to be detected may be a peptide or a protein containing sulfur. In some embodiments, the analyte to be detected may be a peptide or a protein containing the amino acid having one or more sulfur atoms on the side chain or the amino acid having -SH group. The analyte to be detected may be a peptide or a protein containing L-methionine, L-cysteine, L-homocysteine or any other amino acids.
Based strong interaction between Au(III)-thiol, the analyte to be detected may be a thiol. The term “thiol” refers to any molecule that includes one or more terminal -SH group. In some embodiments, the analyte may be a biothiol, which is any thiol that is commonly found in biological systems. Examples of biothiol include amino acids or peptides containing thiol group (-SH), exemplified by cysteine, homocysteine, and glutathione, etc.; several types of antioxidants (such as N-acetylcysteine), and several types of vitamins (such as thiamine).
In some embodiments, the analyte to be detected may be a peptide or a protein containing biothiols or thiols.
The method, the system and the kit of the present invention can be used to discrimination between different analytes, such as different ssDNA, different biothiols or peptides containing different biothiol or thiol, etc.
In this invention, the term “identifying” includes detecting or analyzing the type or the composition of the analyte. For example, the protein nanopore embedded with metal and the method of this invention can be used to detect a metal-containing analyte or analyze the nucleotide composition of a nucleic acid (A, C, G and T). Also, the protein nanopore embedded with metal and the method of this invention can be used to detect the type of the amino acid or analyze the amino acid composition of a peptide or a protein (each amino acid).
This invention also provides systems and methods of identifying an analyte in a sample using protein nanopore. A system and a method of identifying a metal-containing ion in a sample using MspA nanopore is provided when the protein nanopore is MspA nanopore and the analyte is a metal-containing ion. Systems and methods of identifying an analyte in a sample using protein nanopore embedded with metal when the protein nanopore is embedded with metal and the analyte is any analyte discussed herein.
The process of identifying an analyte using protein nanopore is known by the person skilled in the art, which can be used in this invention. Currently known and commonly used methods include positioning a membrane comprising a protein nanopore between a first conductive liquid medium and a second conductive liquid medium, wherein the nanopore comprises an opening that provides liquid communication, applying an electric field across the nanopore and translocating the analyte through the nanopore, measuring the blockade current s of the translocating analyte passed through the nanopore, comparing the experimental blockade current with a blockade current standard and determining the analyte, etc. Any of these steps can be used in the method of this invention and the person skilled in the art knows how to use any of these steps in the method of this invention. This invention is characterized in that the protein used is embedded with metal. Metal embedded protein nanopore amplifies the bolckage io current of the analyte because the channel of the nanopore is narrowed by metal adhesion.
In this invention, for the purpose of identifying an analyte, the protein nanopore may be positioned between a first conductive liquid medium and a second conductive liquid medium, wherein the nanopore comprises an opening that provides liquid communication. Optionally, the first conductive liquid medium and the second conductive liquid medium may be the same or different, either one or both may comprise one or more of a salt, a detergent, or a buffer. For example, in this invention, the first conductive liquid medium and the second conductive liquid medium may be the same and comprises 1.5 M KCl buffer consisting of 1.5 M KCl and 10 mM Tris-HCl at pH=7.0.
In this invention, the protein nanopore may be within a membrane such as a lipid bilayer. The membrane may be positioned between a first conductive liquid medium and a second conductive liquid medium.
The analyte is electrophoretically translocated through the nanopore by virtue of the electrical field that is applied to the nanopore. Process and apparatus for applying an electric field to a nanopore are known to the person skilled in the art. For example, a pair of electrodes may be used to applying an electric field to a nanopore. The electrical field is sufficient to translocate an analyte through the nanopore. As will be understood, the voltage range that can be used can depend on the type of nanopore system and the analyte being used. For example, in some embodiments, the applied electrical field is between about 20 mV and about 200 mV, for protein nanopores. In some embodiments, the applied electrical field is between about 60 mV and about 200 mV. In some embodiments, the applied electrical field is between about 100 mV and about 200 mV. In some embodiments, the applied electrical field is about 180 mV and about 200 mV.
As known by the person skilled in the art, when the analyte translocates through the channel of the nanopore, it interacts with the nanopore, causing a change in the current through the nanopore, which is usually a significant current reduction, known as blockade current. Different molecules will cause different blockade current, which could be used to characterize the composition information about the analyte passing through the nanopore. In general, a “blockade” is evidenced by a change in ion current that is clearly distinguishable from noise fluctuations and is usually associated with the presence of an analyte molecule within the nanopore. The strength of the blockade, or change in current, will depend on a characteristic of the analyte. The person skilled in the art can distinguish which kind of current change is blockade.
In this invention, more particularly, a “blockade” may refer to an interval where the ionic current drops to a level which is about 5-100% lower than the unblocked current level, remains there for a period of time, and returns spontaneously to the unblocked level. For example, the blockade current level may be about, at least about, or at most about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% lower than the unblocked current level.
Methods of measuring blockade current are well known in the art. Measurement of the blockade current through the nanopore may be performed by way of optical signal or electric current signal. For example, one or more measurement electrodes could be used to measure the current through the nanopore. These can be, for example, a patch-clamp amplifier or a data acquisition device. For example, Axopatch-IB patch-clamp amplifier (Axon 200B, Molecular Devices) could be used to measure the electric current flowing through the nanopore.
Those skilled in the art know how to determine the characteristics of an analyte based on the measured blockade current. For example, after the measured blockade current is obtained, said measured blockade current is compared with the blockade current standard and determining the analyte. For example, when the analyte is metal-containing analyte, the measured blockade current is compared with the blockade current standard of metal-containing analyte under the same testing conditions and determining whether the analyte is metal-containing analyte. For example, when the analyte is nucleic acid, the measured blockade current is compared with the blockade current standard of A, T, C and/or G or a combination thereof under the same testing conditions and determining the composition of the nucleic acid. For example, when the analyte is amino acid or peptide, the measured blockade current is compared with the blockade current standard of the amino acid or the peptide under the same testing conditions and determining the type of the amino acid or the composition of the peptide.
The method of the present invention can be qualitative or quantitative. Thus, the method of present invention can be used to determine the identity of the analyte, or the concentration of the analyte. In some embodiments, the method of the present invention can be used to determine the identity of the analyte such as metal-containing ion (e.g. [AuCl4]−, Zn2+, Co2+, Ag+, Cd2+, Ni2+, [AuCl2]−, Cu2+, Cr3+, Fe2+, Fe3+, Pt(II), Pd(II), Mn2°, Hg2+, Ru(II) or Pb2+) or amino acid. For example, when the analyte is metal-contain analyte such as metal-containing ion (e.g. [AuCl4]−, Zn2+, Co2+, Ag+, Cd2+, Ni2+, [AuCl2]−, Cu2+, Cr3+, Fe2+, Fe3+, Pt(II), Pd(II), Mn2+, Hg2+, Ru(II) or Pb2+), the measured blockade current is compared with the blockade current standard of metal-containing ion (e.g. [AuCl4]−, Zn2+, Co2+, Ag+, Cd2+, Ni2+, [AuCl2]−, Cu2+, Cr3+, Fe2+, Fe3+, Pt(II), Pd(II), Mn2+, Hg2++, Ru(II) or Pb2+) under the same testing conditions and determining the identity of metal-containing ion (e.g. [AuCl4]−, Zn2+, Co2+, Ag+, Cd2+, Ni2+, [AUCl2]−, Cu2+, Cr3+, Fe2+, Fe3+, Pt(II), Pd(II), Mn2+, Hg2+, Ru(II) or Pb2+). For example, when the analyte is amino acid, the measured blockade current is compared with the blockade current standard of the amino acid under the same testing conditions and determining the identity of the amino acid. In some embodiments, the method of the present invention can be used to determine the concentration of the analyte such as metal-containing ion (e.g. [AuCl4]−, Zn2+, Co2+, Ag+, Cd2+, Ni2+, [AuCl2]−, Cu2+, Cr3+, Fe2, Fe3+, Pt(II), Pd(II), Mn2+, Hg2+, Ru(II) or Pb2+) or amino acid. For example, when the analyte is metal-containing analyte such as metal-containing ion (e.g. [AuCl4]−, Zn2+, Co2+, Ag+, Cd2+, Ni2+, [AuCl2]−, Cu2+, Cr3+, Fe2+, Fe3+, Pt(II), Pd(II), Mn2+, Hg2+, Ru(II) or Pb2+), the measured blockade current is compared with the blockade current of metal-containing ion (e.g. [AuCl4]−, Zn2+, Co2+, Ag+, Cd2+, Ni2+, [AuCl2]−, Cu2+, Cr3+, Fe2+, Fe3+, Pt(II), Pd(II), Mn2+, Hg2+, Ru(II) or Pb2+) having standard concentration(s) under the same testing conditions and determining the concentration of metal-containing ion (e.g. [AuCl4]−, Zn2+, Co2+, Ag+, Cd2+, Ni2+, [AuCl2]−, Cu2+, Fe2+, Fe3+, Pt(II), Pd(II), Mn2+, Hg2+, Ru(II) or Pb2+). For example, when the analyte is amino acid, the measured blockade current is compared with the blockade current of the amino acid having standard concentration(s) under the same testing conditions and determining the concentration of the amino acid.
According this invention, a method of identifying a metal-containing ion in a sample is provided, the method comprising:
providing a MspA positioned between a first conductive liquid medium and a second conductive liquid medium, wherein the MspA comprises an opening that provides liquid communication between the first conductive liquid medium and the second conductive liquid medium, wherein the first conductive liquid medium or the second conductive liquid medium comprises the sample;
applying an electric field across the MspA and translocating the metal-containing ion through the nanopore;
measuring the blockade current across the nanopore; and
identifying the metal-containing ion in the sample according to the measured blockade current.
According this invention, a system or device of identifying a metal-containing ion in a sample is provided, the system contains a MspA positioned between a first conductive liquid medium and a second conductive liquid medium, wherein the MspA comprises an opening that provides liquid communication between the first conductive liquid medium and the second conductive liquid medium, wherein the first conductive liquid medium or the second conductive liquid medium comprises the sample.
According this invention, a method of identifying an analyte in a sample is provided, the method comprising:
providing a protein nanopore positioned between a first conductive liquid medium and a second conductive liquid medium, wherein the nanopore comprises an opening that provides liquid communication between the first conductive liquid medium and the second conductive liquid medium, wherein the first conductive liquid medium or the second conductive liquid medium comprises the sample, wherein the nanopore is embedded with one or more metal-containing ions;
applying an electric field across the nanopore and translocating the analyte through the nanopore;
measuring the blockade current across the nanopore; and
identifying the analyte in the sample according to the measured blockade current.
According this invention, a system or device of identifying an analyte in a sample is provided, the system or device contains a protein nanopore positioned between a first conductive liquid medium and a second conductive liquid medium, wherein the nanopore comprises an opening that provides liquid communication between the first conductive liquid medium and the second conductive liquid medium, wherein the first conductive liquid medium or the second conductive liquid medium comprises the sample, wherein the nanopore is embedded with one or more metal-containing ions.
The interaction between the embedded metal (such as one or more [AuCl4]−1 ions) and the amino acids on the inner surface of the nanopore can be achieved by applying an electric field and translocating the with metal-containing ion in the nanopore. Thus, in some embodiments, the metal-containing ions may be comprised in the first conductive liquid medium or the second conductive liquid medium together with the analyte to be detected, both the metal-containing ion and the analyte are translocating through the nanopore under the electric field, said metal-containing ion is bound to the inner surface of the nanopore and the analyte is identified.
Thus, one particular embodiment of the method of identifying an analyte in a sample io comprising:
providing a protein nanopore positioned between a first conductive liquid medium and a second conductive liquid medium, wherein the nanopore comprises an opening that provides liquid communication between the first conductive liquid medium and the second conductive liquid medium, wherein the first conductive liquid medium or the second conductive liquid medium comprises the sample and metal-containing ions;
applying an electric field across the nanopore and translocating the metal-containing ions and the analyte through the nanopore;
measuring the blockade current across the nanopore; and
identifying the analyte in the sample according to the measured blockade current.
Thus, one particular embodiment of the system or device of identifying an analyte in a sample contains a protein nanopore positioned between a first conductive liquid medium and a second conductive liquid medium, wherein the nanopore comprises an opening that provides liquid communication between the first conductive liquid medium and the second conductive liquid medium, wherein the first conductive liquid medium or the second conductive liquid medium comprises the sample and metal-containing ions.
In another embodiment, first, the metal-containing ions are allowed to bind to the inner surface of the nanopore, then, the sample is added into the first conductive liquid medium and the second conductive liquid medium and is translocating through the nanopore. Thus, another particular embodiment of the method of identifying an analyte in a sample comprising:
providing a protein nanopore positioned between a first conductive liquid medium and a second conductive liquid medium, wherein the nanopore comprises an opening that provides liquid communication between the first conductive liquid medium and the second conductive liquid medium, wherein the first conductive liquid medium or the second conductive liquid medium comprises metal-containing ions;
applying an electric field across the nanopore and translocating the metal-containing ion through the nanopore;
adding the sample into the conductive liquid medium which comprises the metal-containing ions initially and translocating the analyte through the nanopore;
measuring the blockade current across the nanopore; and
identifying the analyte in the sample according to the measured blockade current.
Thus, another particular embodiment of the system or device of identifying an analyte in a sample contains a protein nanopore positioned between a first conductive liquid medium and a second conductive liquid medium, wherein the nanopore comprises an opening that provides liquid communication between the first conductive liquid medium and the second conductive liquid medium, wherein the first conductive liquid medium or the second conductive liquid medium comprises metal-containing ions.
In some embodiments, said metal-containing ions which will be bound to the inner surface of the nanopore contain Au(III) such as Au3+. In some embodiments, said metal-containing ions are tetrachloroaurate(III) ions (that is [AulC4]−). In some embodiments, chloroauric acid is added into the first or the second conductive liquid medium to form the metal-containing ions. In some embodiments, the concentration of [AuCl4]−1 or chloroauric acid in the first conductive liquid medium or the second conductive liquid medium is equal to or greater than 200 nM, equal to or greater than 1 μM, equal to or greater than 15 μM, or equal to or greater than 10 μM.
In some embodiments, the final concentration of the metal-containing ions in the first conductive liquid medium or the second conductive liquid medium is at least 200nM, at least 1 μM, at least 4 μM, at least 5 μM, at least 8 μM, at least 10 μM, at least 15 μM, at least 50 μM.
The invention also relates to a kit for identifying an analyte, the kit containing: (1) metal-containing compound; and (2) a protein that can form a nanopore or a nucleic acid, expression vector or recombinant host cell that can express a protein that can form a nanopore.
Said metal-containing compound is capable of forming a metal-containing ion in a solution. Said metal-containing ion include metal ion and complex ion formed by metal and other ions. In some embodiments, said metal-containing compound is capable of forming Au(III), Zn2+, Co2+, Ag+, Cd2+, Ni2+, Aum, Cu2+, Cr3+, Fe2+, Fe3+, Pt(II), Pd(II), Mn2+, Hg2+, Ru(II) or Pb2+ in a solution. In some embodiments, said metal-containing compound is capable of forming [AuCl4]− for [AuCl2]− ion in a solution. In some embodiments, said metal-containing compound may be chloroauric acid or tetrachloroaurate(III).
Said protein that can form a nanopore is defined as the same with the above description of protein nanopore.
The embodiments described herein can be understood more readily by reference to the following detailed description, examples, and claims, and their previous and following description. It is to be understood that the embodiments described herein are not limited to the specific uses, methods, and/or products. It is also to be understood that the terminology used herein is for the purpose of describing particular aspects only and is not intended to be limiting.
Further, the following description is provided as an enabling teaching of the various embodiments in their best, currently known aspect. Those skilled in the relevant art will recognize that many changes can be made to the aspects described, while still obtaining the beneficial results of this disclosure. It will also be apparent that some of the desired benefits of the present invention can be obtained by selecting some of the features of the various embodiments without utilizing other features. Accordingly, those who work in the art will recognize that many modifications and adaptations to the various embodiments described herein are possible and can even be desirable in certain circumstances and are a part of the present disclosure. Thus, the following description is provided as illustrative of the principles of the embodiments described herein and not in limitation thereof.
Throughout this application, the term “about” is used to indicate that a value includes the standard deviation of error for the system or method being employed to determine the value. In any embodiment discussed in the context of a numerical value used in conjunction with the term “about,” it is specifically contemplated that the term “about” can be omitted.
It should be understood throughout the present specification that expression of a singular form includes the concept of their plurality unless otherwise mentioned. Accordingly, for example, it should be understood that a singular article (for example, “a”, “an”, “the” in English) comprises the concepts of plural form unless otherwise mentioned.
It should be also understood that the terms as used herein have definitions typically used in the art unless otherwise mentioned. Thus, unless otherwise defined, all scientific and technical terms have the same meanings as those generally used by those skilled in the art to which the present invention pertains. If there is contradiction, the present specification (including the definition) precedes.
All patents and publications, including all sequences disclosed within such patents and publications, referred to herein are expressly incorporated by reference.
The heptameric WT α-HL is a mushroom-shaped ion channel protein with a narrow cylindrical stem with an aperture of −1.4 nm in diameter at its narrowest point[9]. Due to the limited acquisition bandwidth (100 kHz) of a patch clamp amplifier (Axon 200B, Molecular
Devices), translocations of single inorganic ions through nanopores are not resolvable unless an interaction between the ion and the pore can be established. Based on the known sulfur-gold (S—Au) coordination interaction[24], methionine(113)[25-27] which is in the proximity of the 1st restriction site of the pore[28] and is the only sulfur-containing amino acid within the inner surface of an α-HL monomer, is expected to form a reversible interaction with freely translocating tetrachloroaurate(III) ions crossing the membrane.
Experimentally, all electrophysiology measurements were performed with a patch clamp amplifier (Axon 200B, Molecular Devices) in an aqueous buffer consisting of 1.5 M KCl and 10 mM Tris-HCl at pH 7.0, unless otherwise stated (Methods). Chloroauric acid is added into the cis chamber (the side which is electrically grounded) to reach the desired final concentration. With a single WT α-HL inserted in the membrane, the anionic [AuCl4]−1 is electrophoretically driven through the pore. At +100 mV, when chloroauric acid is added to the cis chamber reaching a 5 μM final concentration, binding of [AuCl4]−1 generates characteristic resistive pulse signals (ΔI≈6 pA, τoff≈10-20 seconds, Table 1) (
The measurements are taken with 1 μM HAuCl4 at 100 mV and ΔI1 stands for the amplitude difference between I0 and M-(AuCl4−)1.
To verify this sensing mechanism, a Met→Gly mutation (M113G) was introduced by pore engineering (
To the best of our knowledge, this is the first observation of single molecule coordination interaction between Au(III) and methionine in a confined pore restriction, although systematic investigations on the topic have previously been performed in ensembles[25-27]. Binding of tetrachloroaurate(III) in α-HL shows a wide dispersion in the statistics of the blockage amplitude (
Inspired by nanopore sequencing, where a nanopore with a single, geometrically sharp restriction, as in MspA[22] or CsgG[29] is advantageous because it has a higher spatial resolution[3], direct single ion sensing could also be performed with a geometrically sharp nanopore to acquire an enlarged signal amplitude and avoid non-specific binding with residues distant from the recognition site. The mutant M2 MspA[22] (D93N/D91N/D9ON/D118R/D134R/E139K), which was the first reported nanopore for DNA sequencing, is a funnel shaped, octameric ion channel protein which is ˜1.2 nm in diameter at its narrowest spot (Methods)[30]. The mutations in M2 MspA are designed to neutralize the original negative charges of WT MspA (PDB ID: luun[31]) for an enhanced capture rate for anions, such as DNA[22] or tetrachloroaurate(III). Based on a visual analysis of the corresponding protein structure, no methionine or cysteine exists within the inner surface of M2 MspA, making it a clean “template” to which methionine can be introduced by pore engineering.
Experimentally, as in α-HL M113G (
(D93N/D91M/D9ON/D118R/D134R/E139K), is prepared in the same way as its predecessor (M2 MspA) (Methods) and shows similar channel properties during its characterization (
During continuous electrophysiology recording in 1.5 M KCl buffer with +100 mV applied potential (Methods), [AuCl4]−1 blockage events of MspA-M (
The measurements are taken with 1 μM HAuCl4 at 100 mV. ΔI1 stands for the amplitude difference between I0 and M-(AuCl4−)1.
Considering the existence of eight identical methionine residues as a consequence of the octameric asymmetry of the pore, multi-level blockage events with approximately equal spacing gradually appear when the HAuCl4 concentration is increased further, (
The statistics of event blockage amplitudes, derived from a representative trace with 10 is minutes of continuous recording, show fully resolved peaks, in the form of narrow Gaussian peaks (
Though tetrachloroaurate(III) events are detectable with a 200 nM HAuCl4 concentration in cis, a sharply increased detection frequency is observed (
Embedding different metal ion types within an engineered MspA nanopore is shown in
Engineered MspA nanopore at various locations for AuCl4− embedment is shown in
Single tetrachloroaurate(III) ion binding in different confined spaces Single tetrachloroaurate(III) binding has so far been demonstrated with two types of channel proteins possessing similar outer dimensions but different geometries (
Though the experiment is performed identically, [AuCl4]−1 blockage events in WT a-HL appear as shallow (ΔI=5.63±0.33 pA) resistive pulses but with longer duration and a wide dispersion (12.30±19.23 s) (
The local charge distribution within the inner surface of the pore is critical for analyte attraction. It was found that MspA-M captures tetrachloroaurate(III) more efficiently than WT α-HL, where a 200 nM detection limit is observed from MspA-M, which is 5 times lower than that from α-HL. This may result from the positive charges introduced around the larger vestibule (D118R/D134R/E139K) of MspA-M, which was originally designed to attract ssDNA. [22] Similar phenomena are observed with other biological nanopores, when excessive positive charges in the pore lead to a more efficient DNA capture rate[32-34].
By measuring the voltage dependence for M-(AuCl4−)1 binding events, acquired with either WT α-HL (
On the contrary, [AuCl4]−1 binding in WT α-HL generates significant baseline fluctuations when recorded with more than +100 mV potential bias (
Example 4
By quantitative analysis of the peak amplitude differences (ΔIn=IM-(AuCl
Here ΔIn=IM-(AuCl
Presumably, sequential adhesion of [AuCl4]−1 ions gradually narrows the remaining pore cavity of MspA, making the pore restriction even sharper with the result that any further [AuCl4]−1 blockage signal is amplified with respect to previously accumulated [AuCl4]−1 binding. This phenomenon could be explained semi-quantitatively using finite element method (FEM) modeling by Comsol (
Originally developed for DNA sequencing purposes', fine tuning of the restriction geometry of MspA has not been reported to date. For an [AuCl4]−1 embedded MspA-M, the blockage remains <10%, leaving 90% of the pore cavity open, and possibly still permits ssDNA to translocate. Amplified ssDNA sensing signals are anticipated from the MspA with a narrowed restriction due to the Au(III) embedment. A DNA homopolymer poly(dA)10 (Table 6) was selected as a model analyte to translocate through MspA with a dynamically narrowed Au embedment. Such a short ssDNA homopolymer was selected to avoid complications resulted from DNA secondary structures.
Experimentally, chloroauric acid and poly (dA)10 were added to the cis reaching a final concentration of 10 μM and 8 μM respectively. The electrophysiology recording was carried out at +100 mV in 1.5 M KCl buffer (Methods). As demonstrated in
A scatter plot of ssDNA translocation events extracted from different leveln is presented in
The association rate constant and the mean dwell time and ΔI/I0 for poly(dA)10 with MspA-M in the presence of 10 μM HAuCl4. N=3 to form the statistics.
As reported previously[23], a minimum length of ssDNA (>50 nucleotides) is required for io ssDNA capturing into the MspA nanopore, which has limited its direct sensing applications to short oligomeric nucleic acids, such as miRNA, siRNA or short DNA probes. Pore restriction modulation by dynamic Au(III) embedment demonstrated efficient sensing of short nucleic acid oligomers as short as 10 nucleotides in length. A similar phenomenon is also observed with a 78 nucleotide ssDNA composed of a random sequence (
The mean dwell time and ΔI/I0 for 78-nt ssDNA with MspA-M in the presence of 10 μM HAuCl4.
As reported, the M2 MspA, though possessing a conical geometry, fails to truly resolve a single nucleotide without entanglement with signals from adjacent bases[3], but relies on complicated bioinformatics programs1 for sequence decoding. The accuracy of the decoding is still unsatisfactory compared to next generation sequencing platforms. Nanopore sequencing may be carried out in a MspA nanopore with atomic tuning, where a tighter pore restriction may produce a higher spatial resolution, reduce thermal fluctuations from molecular vibrations or produce more signal characteristics for single nucleotide recognition. However, further engineering of pores with permanent atomic embedment becomes important.
Example 5
Besides modulating the size of the pore restriction, Au(III) embedment also endows the MspA nanopore with new recognition functionalities, such as highly specific sensing of L-methionine by using the embedded Au(III) atom as an atomic adaptor. Although significant attention has been paid to how a protein can be sequenced using nanopores[35], an immediate challenge is to gain the pore restriction with a sensing specificity that fully discriminates 20 amino acids directly from pore blockage events.
Experimentally, the M2 MspA does not report any signal for L-methionine or tetrachloroaurate(III) (
A molecular model which interprets all four types of L-methionine induced blockage events is demonstrated in
Statistics of ΔI1-3.for L-methionine with MspA-M in the presence of 4 μM HAuCl4. at 100 mV. ΔI1-3 stands for the amplitude difference between I0 and [M]-(AuCl4−)-M.
If single tetrachloroaurate(III) binding results in an ˜11 pA drop in the current under these measurement conditions (Table 2), the absolute blockage amplitude from single L-methionine is approximately 37 pA, about 10 times larger in amplitude than was observed in the previously reported amino acid sensing using engineered α-HL.[36, 37] This enlarged pore blockage amplitude from L-methionine results in part from the conical geometry of MspA[36]. However, the Au(III) embedment, which narrows the pore restriction, should also further amplify the pore blockage amplitude due to an increased electric field around the sensing spot where the analyte binds (
This demonstration suggests a new strategy for highly specific amino acid sensing or protein sequencing using nanopores with designed atomic adapters. However, dynamic binding and dissociation of tetrachloroaurate(III) embedment continues to complicate the data analysis. Further engineering with this approach may be done by permanently embedding metal ions using irreversible coordination interactions.[36] Full discrimination of other amino acids can be achieved with designed atomic adaptors targeting different side groups of the analyte amino acids. The locations of these adaptors within a conically shaped biological nanopore could also be widely dispersed to tune the signal amplitude and so optimize signal discrimination.
However, with inevitable existence of isomers, the octameric symmetry of MspA, purifications could be challenging if 2-6 Au(III) atoms are to be introduced into an MspA pore with particular positioning requirements. An alternative solution may simplify the situation by taking the monomeric channel protein OmpG[38-40] as a template for metal ion embedding. Other ion-amino acid combinations within a variety of biological nanopores such as Cytolysin A[41], Phi29 motor protein[42] or aerolysin[2] may also be adapted for different applications.
When bound to a methionine, the Au(III) atom remains in the proximity of the restriction of MspA for ˜0.5 s, forming a transient Au(III) embedment as an adaptor for sensing. Besides the demonstrated Au(III)-thioether interaction, a stronger interaction between Au(III)-thiol is expected, as previously reported[53], which indicates that an Au(III) embedded MspA may sense a variety of thiol-containing molecules. The most abundant biothiols include L-cysteine (Cys), L-homocysteine (Hcy) and L-glutathione (GSH), which are directly involved in crucial physiological processes[54, 55, 56] such as protein synthesis[57], free radical scavenging[54] and normal immune system maintenance[58]. Though presented in the blood plasma with a high abundance, in the ˜μM range[59], the structure similarity of these biothiols presents a great challenge for a direct simultaneous discrimination. With distinct physiological roles, discriminative sensing of these biothiols could have great significance in biomedical diagnostics.
Conventionally, sensing of biothiols was performed with high performance liquid chromatography-mass spectroscopy[60] or designed fluorescence probes[61], but suffers from a time consuming and laborious sample preparation process or the challenge of probe design.
Nanopore sensing, which is inexpensive, fast and has advantages in the resolution of minor structural differences in small molecules, may provide an alternative solution for direct sensing of biothiols. However, a biological nanopore, such as an octameric MspA-M, doesn't directly report signals for all biothiols in general (
On the other hand, the demonstrated Au(III) embedment enables MspA to interact with biothiols via the Au(III)-thiol coordination chemistry. The Au(III)-thiol coordination, which forms a much stronger bond than the established Au(III)-thioether coordination, competes with the existing Au(III)-thioether bond and consequently speeds up the dissociation of the Au(III) from the pore. Though the described chemical process happens rapidly, it can be monitored by a nanopore sensor, which forms the basis for sensing.
As a proof of concept, nanopore-based biothiol sensing was carried out with MspA-M as described in Methods. Specifically, HAuCl4 was added to the cis while the biothiols were s added in the trans compartment. The two analytes were added to different sides of a nanopore to minimize the spontaneous redox reactions between Au(III) and biothiols before entering the pore restriction (
L-cysteine (Cys), which is an essential amino acid involved in protein synthesis[57], is the most well-known biothiol (
With their characteristic event shape, Cys sensing events can be immediately distinguished from other non-specific binding types. To ensure the readability, only Cys sensing events were counted in the statistics which were based on a simple algorithm that an event has to contain all three states as demonstrated in
Similar measurements were also performed with L-asparagine, L-glycine and L-glutamic acid (
The statistical data were from 10 min continuous recordings with MspA-M when 4 μM HAuCl4 were placed in cis and 40 μM Cys were placed in trans. A +100 mV voltage was applied. ΔI0-1 stands for the amplitude difference between I0 and I1. ΔI0-1,Cys stands for the amplitude difference between I0 and I1,Cys. τoff stands for the dwell time of I1, τoff,Cys stands for the dwell time of I1,Cys. Three independent measurements were performed for each condition to form the statistics.
The statistical data were from 10 min continuous recordings with MspA-M when 4 μM HAuCl4 were placed in cis and 40 μM Cys were placed in trans. A +100 mV voltage was applied. ΔI0-1 stands for the amplitude difference between I0 and ΔI0-1,Cys stands for the amplitude difference between I0 and Ia,Cys. Three independent measurements were performed for each condition to form the statistics.
L-Homocysteine (Hcy), which is a homologue of Cys, is an important intermediate in the metabolism of methionine and cysteine[62]. An elevated Hcy level in the blood serum indicates a high risk of cardiovascular diseases and is a critical parameter in diagnosis[63]. However, Hcy differs from Cys with just one additional methylene group (
Hcy sensing was performed as described in
To demonstrate simultaneous discrimination between Cys and Hcy from direct single molecule readouts, a nanopore measurement was performed with a mixure of 20 μM Cys and 20 μM Hcy in trans. The concentration of HAuCl4 in cis was kept at 4 μM. The addition of two types of biothiols immediately reports two distinguishable event types as demonstrated from a continuously recorded trace (
The statistical data were from 10 min continuous recordings with MspA-M when 4 μM HAuCl4 were placed in cis and 40 μM Hcy were placed in trans. A+100 mV voltage was applied. ΔI0-1 stands for the amplitude difference between /0 and h. 0/0-1,Hcy stands for the amplitude difference between /0 and luicy. . Toff stands for the dwell time of h, Toff,cys stands for the dwell time of I1,Hcy. Three independent measurements were performed for each condition to form the statistics.
The statistical data were from 10 min continuous recordings with MspA-M when 4 μM HAuCl4 were placed in cis and 40 μM Hcy were placed in trans. A +100 mV voltage was applied. ΔI0-1 stands for the amplitude difference between I0 and I1. ΔI0-1,Hcy stands for the amplitude difference between I0 and I1,Hcy. Three independent measurements were performed for each condition to form the statistics.
The statistical data were from 10 min continuous recordings with MspA-M when 4 μM HAuCl4 were placed in cis and 40 μM GSH were placed in trans. A +100 mV voltage was applied. ΔI0-1 stands for the amplitude difference between I0 and I1. ΔI1, ΔI0-1GSH stands for the amplitude difference between I0 and I1,GsH. τoff stands for the dwell time of I1, τoff,Cys stands for the dwell time of I1,GsH. Three independent measurements were performed for each condition to form the statistics.
Direct sensing of L-Glutathione by Au(III) Embedded MspA
L-Glutathione (GSH), which is a tripeptide (Glu-Cys-Gly) (
With 4 μM chloroauric acid in cis and 40 μM GSH in trans, characteristic biothiol sensing events measuring ˜36 pA in amplitude were observed (
Simultaneous discrimination of Cys and GSH was performed by adding a mixture of Cys and GSH in trans with 10 μM and 30 μM final concentrations respectively, while HAuChin cis remained at 4 μM. Compared with Cys or Hcy, GSH has a larger molecular weight and is negatively charged in a pH neutral buffer. With a +100 mV applied voltage, it was found that Cys is much more likely than GSH to be captured by the Au(III) embedded nanopore so that the GSH concentration in the mixture was increased to balance the rate of appearance of both events. From the electrophysiology trace, two types of events were clearly identified according to the difference in their amplitudes (
The sensing events of three types of biothiols are summarized in
The histogram of ΔI/I0 for Cys, Hcy and GSH events with corresponding Gaussian fittings are shown in
From the histogram in
Distinct from a recent report of cysteine and homocysteine discrimination using nanopores[64], in which a time consuming sample preparation is needed and GSH was in principle not detectable, the described method in this invention suggests a strategy that is simple and straightforward, which could sense a wide variety of proteins containing biothiols or thiols using nanopores with designed atomic adapters. However, dynamic binding and dissociation of Au(III) embedment continues to complicate the data analysis, which makes it difficult to quantify biothiols reliably. Further engineering with this approach may be done by permanently embedding metal ions using irreversible coordination adaptors[65]. Full discrimination of other amino acids may be achieved with designed atomic adaptors targeting different side groups of the amino acid analytes. The locations of these adaptors within a conically shaped biological nanopore may also be slightly dispersed so that the signal amplitude from different analyte may be tuned to assist full discrimination.
The statistical data were from 10 min continuous recordings with MspA-M when 4 μM HAuCl4 were placed in cis and 40 μM GSH were placed in trans. A +100 mV voltage was applied. A/0-1 stands for the amplitude difference between I0 and I1. ΔI0-1,GSH stands for the amplitude difference between I0 and I1,GSH. Three independent measurements were performed for each condition to form the statistics.
We have demonstrated the first polyatomic ion sensing using WT αHL. The observed io single molecule coordination interaction between Au(III) and methionine may inspire the design of new gold-containing compounds as drugs which target ion channel proteins. This molecular mechanism could also be transplanted into other biological nanopores such as MspA. As a consequence of geometric optimization, binding of single tetrachloroaurate(III) ions results in enlarged, consistent and sharply distributed blockage signals. The observed tetrachloroaurate(III) binding event in MspA at +200 mV also includes the largest single ion blockage signal (˜54.88 pA) to have ever been demonstrated. The sharp restriction of MspA along with the simplicity of mutagenesis suggests its role as a new engineering template to sense a wide variety of single ions and other small molecules, complementary to its well-known uses in nanopore sequencing.
When embedded with Au(III), the translocation characteristics of ssDNA could be gradually modulated when the restriction is atomically narrowed by further [AuCl4]− embedment as a consequence of geometric modulation. We also demonstrate highly specific recognition of L-methionine by MspA-M when embedded with a single tetrachloroaurate(III) ion, which suggests a new recognition functionalization strategy in nanopore based protein sequencing.
With its unique physical and chemical properties, gold has been used extensively in a wide range of scientific and industrial applications such as production of nanoparticles[43], tunneling electrodes[44], surface enhanced raman spectroscopy probes[45] and surface plasmonic resonance substrates[46]. However, these technologies lack single molecule control precision comparable to that offered by a biological nanopore, in which the geometry[47], orientation[48], polarity[41] and chemical modifications[10] of both the pore and the analyte can be manipulated. By taking the embedded Au(III) as an atomic bridge, MspA is enabled with biothiol-sensing capacities which directly discriminate between L-cysteine, L-homocysteine and L-glutathione from single molecule readouts. Though demonstrated as a proof of principle, this sensing mechanism is simple, label free, fast and economic and may be engineered into a portable sensor chip. With this first report of insertion of Au into an engineered biological nanopore with atomic precision and flexibility, this technology may benefit a wide range of scientific research projects in need of single molecule precision and the properties from gold[49, 50] or even other metal elements if properly designed.
Hexadecane, pentane, ethylenediaminetetraacetic acid (EDTA), Triton X-100, Genapol X-80 and hydrogen tetrachloroaurate (III) hydrate (99.99%) and L-Glutathione reduced were obtained from Sigma-Aldrich. 1,2-diphytanoyl-sn-glycero-3-phosphocholine (DPhPC) was from Avanti Polar Lipids. Dioxane-free isopropyl-P-D-thiogalactopyranoside (IPTG), to kanamycin sulfate, imidazole and tris(hydroxymethyl)aminomethane (Tris) were from Solarbio. 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) was from Shanghai Yuanye Biotechnology (China). E. coli strain BL21 (DE3) were from Biomed. LB broth and LB agar were from Hopebio (China). Hydrochloric acid (HC1) was from Sinopharm (China). L-methionine, L-asparagine, L-glycine, L-cysteine, and L-glutamic acid were from BBI Life Sciences (China). L-Homocysteine was from J & K Chemical Technology.
The potassium chloride buffer (1.5 M KCl, 10 mM Tris-HCl, pH 7.0) was prepared with Milli-Q water and membrane (0.2 μm, Whatman) filtered prior to use. HPLC-purified ssDNA (Genescript, New Jersey, Table 6) was dissolved in Milli-Q water without further purification. Hydrogen tetrachloroaurate (III) hydrate was dissolved in Milli-Q water as a stock solution (30 mM) for subsequent experiments. L-methionine, L-asparagine and L-glycine were dissolved in Milli-Q water as stock solutions (20 mM) for subsequent experiments. L-cysteine, L-asparagine, L-glycine, L-glutamic aicd L-homocysteine and L-glutathione reduced were dissolved in the potassium chloride buffer at 5 mM final concentration for subsequent experiments.
The gene coding for α-HL WT and α-HL M113G were custom synthesized and constructed in a pet 30a(+) plasmid (Genescript, New Jersey) for prokaryotic protein expression. Heptameric α-HL were expressed with E. coli BL21 (DE3) and purified with nickel affinity chromatography as previously published[51]. After heat shock transformation with plasmid gene coding for either α-HL WT or α-HL M113G, the cells were grown in LB medium at 37° C. till OD600=0.7. Isopropyl P-D-thiogalactoside (IPTG) was then added to a final concentration of 1 mM for induction. After shaking overnight at 18° C., the cells were harvested by centrifugation (4000 rpm, 20 min, 4° C.). The pellet was collected and re-suspended in lysis buffer 1 (0.5 M NaCl, 20 mM HEPES, 1% Triton X-100, pH=8.0), sonicated for 15 min and then centrifuged (14,000 rpm, 4° C., 40 min) to remove intact cells. After syringe filtration, the supernatant was loaded onto a nickel affinity column (HisTrapTM HP, GE Healthcare). After washing the column with buffer Al (0.5 M NaCl, 20 mM HEPES, 5 mM imidazole pH 8.0), the α-HL heptamers were then eluted with a linear gradient of imidazole to buffer B1 (0.5 M NaCl, 20 mM HEPES, 500 mM imidazole, pH 8.0). Fractions of interests were further characterized and confirmed with SDS-polyacrylamide gel electrophoresis (
The gene codings for M2 MspA (D93N/D91N/D9ON/D118R/D134R/E139K) and MspA-M (D93N/D91M/D9ON/D118R/D134R/E139K) were custom synthesized and constructed in a pet 30a(+) plasmid (Genescript, New Jersey) for prokaryotic protein expression as previously published[51]. After heat shock transformation with plasmid gene coding for either M2 MspA or MspA-M, the cells were grown in LB medium to an OD600=0.7, induced with by 1 mM isopropyl P-D-thiogalactoside (IPTG) and shaken overnight at 16 ° C. The cells were harvested by centrifugation (4000 rpm, 20 min, 4° C.) and the pellet was re-suspended in lysis buffer 2 (100 mM Na2HPO4/NaH2PO4, 0.1 mM EDTA, 150 mM NaCl, 0.5% (w/v) Genapol X-80, pH 6.5), and heated to 60° C. for 10 min. The suspension was cooled on ice for 10 min and io centrifuged at 4° C. for 40 min at 13,000 rpm. After syringe filtration, the supernatant was applied to a nickel affinity column (HisTrapTM HP, GE Healthcare). After washing the column with buffer A2 (0.5 M NaCl, 20 mM HEPES, 5 mM imidazole, 0.5% (w/v) Genapol X-80, pH=8.0), bound proteins were eluted with a linear gradient of imidazole to buffer B2 (500 mM imidazole, 0.5 M NaCl, 20 mM HEPES, 0.5% (w/v) Genapol X- is 80, pH=8.0). The fractions for MspA octamer were collected and characterized by 12% SDS-PAGE (
Electrophysiology Recording and data analysis
All electrophysiology results were acquired by an Axopatch 200B patch clamp amplifier and digitized by a Digidata 1550 Al digitizer (Molecular Devices, UK). A custom made measurement chamber is separated by a Teflon film (30 pm thick) with an orifice (6=100 pm). Before use, the orifice was pretreated with 0.5% (v/v) hexadecane in pentane and then air-dried to evaporate the pentane. 1,2-Diphytanoyl-sn-glycero-3-phosphocholine (DphPC) was used to form a self-assembled lipid bilayer sealing the orifice. This lipid bilayer divides the chamber into cis and trans compartments both filled with 0.5 mL of 1.5 M KC1 buffer (1.5 M KC1, 10 mM Tris-HCl, pH 7.0). A pair of Ag/AgCl electrodes were placed in cis and trans side of the chamber, in contact with the aqueous buffer respectively. Biological nanopores (WT a-HL, α-HL M113G, M2 MspA or MspA-M) were added to cis for spontaneous pore insertion.
For [AuCl4]−1 binding experiments, the acquired single channel data was sampled at 25 kHz and filtered with a corner frequency of 1 kHz. For [AuCl4]−1 binding events, the recorded current traces were digitally filtered with a 200 Hz low-pass Bessel filter (eight-pole) and the events were detected by the single-channel search feature in Clampfit 10.7 (Axon Instruments).
For ssDNA translocation experiments, the data was sampled at 250 kHz and filtered with a corner frequency of 100 kHz. For ssDNA translocation events, the recorded current traces were digitally filtered with a 10 kHz low-pass Bessel filter (eight-pole) and the events were detected by the single-channel search feature in Clampfit 10.7 (Axon Instruments). Further analyses (histogram, curve fitting and plotting) were carried out in Origin 9.1 (Origin Lab).
For specific sensing of L-methionine, the data was sampled at 25 kHz and filtered with a corner frequency of 1 kHz. Event states 1-3 were detected by the single channel search feature in Clampfit 10.7. Further analysis was carried out in Origin 9.1.
For specific sensing of L-glutamic aicd L-homocysteine and L-glutathione, all measurements were performed with a +100 mV continuously applied voltage. The acquired single channel data was sampled at 25 kHz and filtered with a corner frequency of 1 kHz. The recorded current traces were digitally filtered with a 0.2 kHz low-pass Bessel filter (eight-pole). Event states were detected by the single channel search feature in Clampfit 10.7 and further analyses (histogram, curve fitting and plotting) were carried out in Origin 9.1 (Origin Lab).
Academy of Sciences 107, 16060-16065 (2010).
Nanoparticulate TiO2 - Filmed Ultramicroelectrode. Angewandte Chemie International Edition 57, 3758-3762 (2018).
Imaging in Live Cells. Journal of the American Chemical Society 140, 5385-5392 (2018).
Number | Date | Country | Kind |
---|---|---|---|
PCT/CN2018/102709 | Aug 2018 | CN | national |
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/CN2019/102756 | 8/27/2019 | WO | 00 |